Improving the potency prediction for chemically modified siRNAs through insights from molecular modeling of individual sequence positions

Chemical modifications are applied to small interfering RNAs (siRNAs) to improve their metabolic stability, specificity, and duration of pharmacodynamic effects. Despite tremendous progress made, identifying chemically modified siRNAs with drug-like properties requires empirical screening due to an intricate interdependence of siRNA sequence and chemistry, i.e., the nature and position of chemical modifications within the siRNA duplex. To improve our ability to design fully modified, potent siRNAs, we combined experimental measurements of thermodynamic stability and biological activity <i>in vitro</i> with extensive molecular modeling <i>in silico</i> of the structural, dynamic, and energetic properties of parent (unmodified) siRNA duplex sequences compared with their chemically modified variants. A pattern of modifications at specific positions were identified, where the combination of sequence and chemical modifications play an outsized role in the observed biological activity. Molecular modeling revealed low stabilization energies and increased sugar stereochemical flexibility for 2'-F modified position g2 and less so for g6 in the guide strand seed region. Machine learning confirmed that these properties correlate with higher observed biological activity. These results provide molecular-level insights into the effects of chemical modifications on the intrinsic activity of siRNAs, which can be used in the rational design of chemically modified siRNAs with uncompromised potency.

Authors

Institutions

Publication Details

Journal
Molecular Therapy — Nucleic Acids
Published
2024-12-06
DOI
https://doi.org/10.1016/j.omtn.2024.102415
Citations
10
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
2.34

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Improving the potency prediction for chemically modified siRNAs through insights from molecular modeling of individual sequence positions

Scott Waldron, Valeri Barsegov, Adam Castoreno, Evgenii Kliuchnikov et al.
10 citations
Molecular Therapy — Nucleic Acids
RNA Interference and Gene Delivery
2.34
article

Improving the potency prediction for chemically modified siRNAs through insights from molecular modeling of individual sequence positions

Scott Waldron, Valeri Barsegov, Adam Castoreno, Evgenii Kliuchnikov, Mark K. Schlegel, Sarah Hyde, Farkhad Maksudov, Martin A. Maier, Kenneth A. Marx, Jeffrey Zuber
article en
10 citations

Abstract

Chemical modifications are applied to small interfering RNAs (siRNAs) to improve their metabolic stability, specificity, and duration of pharmacodynamic effects. Despite tremendous progress made, identifying chemically modified siRNAs with drug-like properties requires empirical screening due to an intricate interdependence of siRNA sequence and chemistry, i.e., the nature and position of chemical modifications within the siRNA duplex. To improve our ability to design fully modified, potent siRNAs, we combined experimental measurements of thermodynamic stability and biological activity <i>in vitro</i> with extensive molecular modeling <i>in silico</i> of the structural, dynamic, and energetic properties of parent (unmodified) siRNA duplex sequences compared with their chemically modified variants. A pattern of modifications at specific positions were identified, where the combination of sequence and chemical modifications play an outsized role in the observed biological activity. Molecular modeling revealed low stabilization energies and increased sugar stereochemical flexibility for 2'-F modified position g2 and less so for g6 in the guide strand seed region. Machine learning confirmed that these properties correlate with higher observed biological activity. These results provide molecular-level insights into the effects of chemical modifications on the intrinsic activity of siRNAs, which can be used in the rational design of chemically modified siRNAs with uncompromised potency.

Molecular Therapy — Nucleic AcidsVol. 36(1)
University of Massachusetts Lowell (US), Alnylam Pharmaceuticals (United States) (US)
Alnylam Pharmaceuticals
Zero hunger
Openalex Percentile: Top 11%
RNA Interference and Gene Delivery
2.34
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.